Article
Author(s):
Chicago - Escalating doses of an antibody to CTLA-4 in conjunction with a peptide vaccine showed the induction of antigen-specific immune responses and potential evidence of autoimmunity in patients with stage III/IV resected melanoma, according to Jeffrey M. Weber, M.D., Ph.D.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.